{"schema_version":"secwatch.filing_event.v1","accession":"0001384101-24-000004","form_type":"8-K","ticker":"VCYT","cik":"0001384101","company_name":"VERACYTE, INC.","filed_at":"2024-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.014252+00:00","generated_at":"2026-06-06T07:57:15.887894+00:00","sec_items":["2.01","9.01","3.02"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Veracyte completes $70M acquisition of C2i Genomics; milestone payments up to $25M","bullets":["Purchase price of $70M paid to C2i Genomics securityholders, subject to customary adjustments.","Up to $25M in additional milestone payments payable in cash or stock over next two years.","Veracyte to issue up to 2,698,349 shares as stock consideration; cash in lieu for non-accredited investors.","SEC granted partial waiver from certain financial statement requirements under Rule 3-13.","Closing occurred on February 5, 2024; audited C2i financials to be filed within 71 days."],"urls":{"canonical":"https://secwatch.observer/filing/0001384101-24-000004","json":"https://secwatch.observer/filing/0001384101-24-000004.json","markdown":"https://secwatch.observer/filing/0001384101-24-000004.md","text":"https://secwatch.observer/filing/0001384101-24-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1384101/000138410124000004/0001384101-24-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1384101/000138410124000004/vcyt-20240205.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T07:57:15.887894+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"29a7473a5c9153463a5334aa7c385017a32a3c01","claim":"VERACYTE, INC. completed an acquisition involving C2i Genomics, Inc. for $70.0 million (closed 2024-02-05).","evidence_excerpt":"On February 5, 2024 (the “Closing Date”), Veracyte, Inc., a Delaware corporation (“Veracyte”), completed its previously announced acquisition of C2i Genomics, Inc., a Delaware corporation (“C2i Genomics”), for a purchase price of $70.0 million","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1384101/000138410124000004/0001384101-24-000004-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"C2i Genomics, Inc."},{"label":"Consideration","value":"$70.0 million"},{"label":"Closing","value":"2024-02-05"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}